{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:30:46Z","timestamp":1767893446410,"version":"3.49.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>This analysis assessed the safety of intravenous immunoglobulin (IVIg) in the treatment of patients with neuroimmunological and immunological disorders in a home-based setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Adverse reactions (ARs) were assessed in a retrospective review of 1176 patients receiving 28,677 home-based IVIg infusions between 1996 and 2013.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 1176 patients, 648 (55.1%) experienced IVIg-related ARs; 536 (45.6%) were mild, 78 (6.6%) moderate, and 34 (2.9%) severe. Thirty-seven (3.1%) patients were hospitalized because of ARs; of these, headache was most common (51.4%). Mean number of ARs per patient increased from 1.4 (low dose) to 3.6 (high dose). Incidence of ARs increased from 41% in the first 5-year moving average in 2003 to 65% in 2008. The number of ARs correlated with the number of infusions (\u03c1 = 0.24; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and the average IVIg dose (\u03c1 = 0.10; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Low- and high-dose IVIg were safe and well tolerated with a few serious ARs in patients with neuroimmunological and immunological disorders.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0000000000000201","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T19:25:45Z","timestamp":1527103545000},"page":"181-195","source":"Crossref","is-referenced-by-count":5,"title":["A Retrospective Analysis of the Safety Profile of Intravenous Immunoglobulin in 1176 Patients Receiving Home Infusion Therapy"],"prefix":"10.1097","volume":"19","author":[{"given":"Nizar","family":"Souayah","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurosciences, Rutgers New Jersey Medical School, Newark, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Pahwa","sequence":"additional","affiliation":[{"name":"Innovative Research Associates, Philadelphia, PA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Burawski","sequence":"additional","affiliation":[{"name":"Innovative Research Associates, Philadelphia, PA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Opila","sequence":"additional","affiliation":[{"name":"Innovative Research Associates, Philadelphia, PA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard W.","family":"Sander","sequence":"additional","affiliation":[{"name":"Department of Neurology, New York University School of Medicine, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230902","first-page":"1","article-title":"IVIG medication safety: a stepwise guide to product selection and use","author":"Siegel","year":"2010","journal-title":"Pharm Pract News."},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.intimp.2016.12.030","article-title":"Rapid infusions of human normal immunoglobulin 50 g\/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia","volume":"44","author":"Spadaro","year":"2017","journal-title":"Int Immunopharmacol."},{"issue":"suppl 4","key":"R5-20230902","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/CND.0b013e3182212589","article-title":"The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders","volume":"12","author":"Souayah","year":"2011","journal-title":"J Clin Neuromuscul Dis."},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/CND.0b013e31818b2aef","article-title":"Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions","volume":"10","author":"Rigas","year":"2008","journal-title":"J Clin Neuromuscul Dis."},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF01541739","article-title":"Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home","volume":"15","author":"Brennan","year":"1995","journal-title":"J Clin Immunol."},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1542\/peds.85.5.705","article-title":"Home self-administration of intravenous immunoglobulin therapy in children","volume":"85","author":"Kobayashi","year":"1990","journal-title":"Pediatrics"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2004.06.003","article-title":"Intravenous immunoglobulin and the kidney\u2014a two-edged sword","volume":"34","author":"Orbach","year":"2004","journal-title":"Semin Arthritis Rheum."},{"key":"R10-20230902","first-page":"24","article-title":"Human immunoglobulins, adverse drug reaction, prevention [in French]","volume":"29","author":"Grenouillet-Delacrea","year":"2008","journal-title":"Rev Med Interne."},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00005-016-0410-1","article-title":"Anaphylaxis to IVIG","volume":"65","author":"Williams","year":"2017","journal-title":"Arch Immunol Ther Exp (Warsz)."},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0002-9343(84)90324-3","article-title":"Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases","volume":"76","author":"Ochs","year":"1984","journal-title":"Am J Med."},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency Committee of the American Academy of allergy, asthma and immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"R15-20230902","first-page":"953","article-title":"Adverse reactions of intravenous immunoglobulin","volume":"21","author":"Al-Wahadneh","year":"2000","journal-title":"Saudi Med J."},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol."},{"key":"R17-20230902","first-page":"173","article-title":"Adverse events during treatment with high-dose intravenous immunoglobulins for neurological disorders","volume":"40","author":"Stangel","year":"1998","journal-title":"Eur Neurol."},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.0.CO;2-N","article-title":"Complications of intravenous gammaglobulin in neuromuscular and other diseases","volume":"19","author":"Bertorini","year":"1996","journal-title":"Muscle Nerve."},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.inf.0000223517.98486.2f","article-title":"Intravenous immunoglobulin: production, uses and side effects","volume":"25","author":"Cowden","year":"2006","journal-title":"Pediatr Infect Dis J."},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2165\/00002018-199309040-00003","article-title":"Adverse effects of intravenous immunoglobulin","volume":"9","author":"Misbah","year":"1993","journal-title":"Drug Saf."},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000056085","article-title":"Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases","volume":"62","author":"Sherer","year":"2001","journal-title":"Pharmacology"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","article-title":"Adverse events associated with intravenous immunoglobulin therapy","volume":"6","author":"Hamrock","year":"2006","journal-title":"Int Immunopharmacol."},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","article-title":"Side effects of intravenous immunoglobulins in neurological autoimmune disorders\u2014a prospective study","volume":"250","author":"Stangel","year":"2003","journal-title":"J Neurol."},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med."},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1027380210989","article-title":"Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases","volume":"17","author":"Schiff","year":"1997","journal-title":"J Clin Immunol."},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev."},{"key":"R28-20230902","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","article-title":"Intravenous immunoglobulin: adverse reactions and management","volume":"122","author":"Bonilla","year":"2008","journal-title":"J Allergy Clin Immunol."},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1423-0410.1998.7420074.x","article-title":"IVIG adverse reactions: potential role of cytokines and vasoactive substances","volume":"74","author":"Bagdasarian","year":"1998","journal-title":"Vox Sang."},{"key":"R30-20230902","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00129804-200507000-00009","article-title":"Developing practice guidelines for the administration of intravenous immunoglobulin","volume":"28","author":"Murphy","year":"2005","journal-title":"J Infus Nurs."},{"key":"R31-20230902","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.it.2008.08.004","article-title":"Modulation of the cellular immune system by intravenous immunoglobulin","volume":"29","author":"Tha-In","year":"2008","journal-title":"Trends Immunol."},{"key":"R32-20230902","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.intimp.2005.11.003","article-title":"Differences between IGIV products: impact on clinical outcome","volume":"6","author":"Gelfand","year":"2006","journal-title":"Int Immunopharmacol."},{"key":"R33-20230902","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1345\/aph.1K037","article-title":"Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders","volume":"41","author":"Gurcan","year":"2007","journal-title":"Ann Pharmacother."},{"key":"R34-20230902","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","article-title":"Venous and arterial thrombosis following administration of intravenous immunoglobulins","volume":"16","author":"Paran","year":"2005","journal-title":"Blood Coagul Fibrinolysis."},{"key":"R35-20230902","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1160\/TH06-09-0503","article-title":"Intravenous immunoglobulin-associated vena cava thrombosis","volume":"96","author":"Marie","year":"2006","journal-title":"Thromb Haemost."},{"key":"R36-20230902","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol."},{"key":"R37-20230902","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1191\/0961203303lu2168rr","article-title":"Review: intravenous immunoglobulin therapy and thromboembolic complications","volume":"14","author":"Katz","year":"2005","journal-title":"Lupus"},{"key":"R38-20230902","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archderm.142.2.213","article-title":"Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature","volume":"142","author":"Vecchietti","year":"2006","journal-title":"Arch Dermatol."},{"key":"R39-20230902","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4065\/72.12.1151","article-title":"Intravenous immunoglobulininduced lichenoid dermatitis: a unique adverse reaction","volume":"72","author":"Yockey","year":"1997","journal-title":"Mayo Clin Proc."},{"key":"R40-20230902","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0140-6736(87)90627-1","article-title":"Alopecia after immunoglobulin infusion","volume":"1","author":"Chan-Lam","year":"1987","journal-title":"Lancet"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00131402-201806000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T05:14:11Z","timestamp":1693631651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201806000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000201","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}